First human test: can liver patients safely take new blood disorder drug?
NCT ID NCT07480824
Summary
This early study aims to understand how a single dose of the experimental drug TQ05105 is processed by the body in people with mild or moderate liver problems, compared to healthy people. It will involve 24 adults to measure drug levels in the blood and check for safety. The goal is to gather basic information on how liver health affects this potential treatment for myelofibrosis, a serious bone marrow disorder.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, 471000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
Jinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.